Legend Biotech Corporation (LEGN)

Basic

  • Market Cap

    $11.32B

  • EV

    $10.21B

  • Shares Out

    181.79M

  • Revenue

    $233.31M

  • Employees

    1,700

Margins

  • Gross

    -110.88%

  • EBITDA

    -188.29%

  • Operating

    -192.77%

  • Pre-Tax

    -218.18%

  • Net

    -218.3%

  • FCF

    -158.44%

Returns (5Yr Avg)

  • ROA

    -20.84%

  • ROE

    -68.64%

  • ROCE

    -44.12%

  • ROIC

    -100.02%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $87.69

  • P/E

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • EV/FCF

    —

Per Share

  • Rev

    $1.36

  • Earnings (Dil)

    -$2.96

  • FCF

    -$2.15

  • Book Value

    $7.37

Growth (CAGR)

  • Rev 3Yr

    58.42%

  • Rev 5Yr

    37.63%

  • Rev 10Yr

    —

  • Dil EPS 3Yr

    1.74%

  • Dil EPS 5Yr

    130.86%

  • Dil EPS 10Yr

    —

  • Rev Fwd 2Yr

    127.1%

  • EBITDA Fwd 2Yr

    —

  • EPS Fwd 2Yr

    —

  • EPS LT Growth Est

    —

Dividends

  • Yield

    —

  • Payout

    —

  • DPS

    —

  • DPS Growth 3Yr

    —

  • DPS Growth 5Yr

    —

  • DPS Growth 10Yr

    —

  • DPS Growth Fwd 2Yr

    —

Select a metric from the list below to chart it

Dec '17
Dec '18
Jan '20
Dec '20
Dec '21
Dec '22
LTM
Metric
Dec '17
Dec '18
Jan '20
Dec '20
Dec '21
Dec '22
LTM

Revenues

49.1

60.0

75.0

65.4

116.7

233.0

Other Revenues, Total

0.4

1.8

—

3.4

0.3

0.3

Total Revenues

49.5

61.8

75.0

68.8

117.0

233.3

Total Revenues % Chg.

108.9%

24.9%

21.4%

-8.2%

70.0%

120.3%

Cost of Goods Sold, Total

—

—

232.2

313.3

401.0

492.0

Gross Profit

49.5

61.8

-157.2

-244.5

-284.0

-258.7

Selling General & Admin Expenses, Total

3.9

32.4

72.7

149.5

174.0

191.0

R&D Expenses

60.6

161.9

—

—

—

—

Other Operating Expenses, Total

64.6

194.3

72.7

149.5

174.0

191.0

Operating Income

-15.1

-132.5

-229.9

-394.0

-458.1

-449.8

Interest Expense, Total

-0.1

-0.2

-0.2

-0.9

-10.8

-20.8

Interest And Investment Income

6.2

4.6

2.9

1.0

8.2

42.1

Net Interest Expenses

6.1

4.4

2.7

0.1

-2.6

21.2

Currency Exchange Gains (Loss)

7.2

0.6

0.1

—

—

10.1

Other Non Operating Income (Expenses)

-0.0

-0.2

-1.2

-12.3

14.8

-91.5

EBT, Excl. Unusual Items

-1.7

-127.8

-228.3

-406.2

-445.8

-509.8

Gain (Loss) On Sale Of Investments

0.1

0.5

0.0

—

0.6

1.3

Gain (Loss) On Sale Of Assets

—

—

-0.1

-1.0

-0.5

-0.5

Other Unusual Items

—

—

-80.0

—

—

—

EBT, Incl. Unusual Items

-1.6

-127.3

-308.3

-407.2

-445.7

-509.0

Income Tax Expense

1.2

-25.7

-41.9

-3.6

0.6

0.3

Earnings From Continuing Operations

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Net Income

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Net Income to Common Incl Extra Items

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Net Income to Common Excl. Extra Items

-2.8

-101.6

-266.4

-403.6

-446.3

-509.3

Total Shares Outstanding

100.0

100.0

133.0

154.2

165.1

181.8

Weighted Avg. Shares Outstanding

100.0

100.0

118.2

140.9

159.0

171.9

Weighted Avg. Shares Outstanding Dil

100.0

100.0

118.2

140.9

159.0

171.9

EPS

-0.0

-1.0

-2.3

-2.9

-2.8

-3.0

EPS Diluted

-0.0

-1.0

-2.3

-2.9

-2.8

-3.0

EBITDA

-14.2

-129.4

-223.6

-385.9

-447.9

-439.3